A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of a 200-mcg Dose

NCT00001056 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: gp160 Vaccine (Immuno-AG)

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]